CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN
✉ Email this page to a colleague
All Clinical Trials for DAPAGLIFLOZIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00162305 ↗ | A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects | Completed | Bristol-Myers Squibb | Phase 2 | 2005-04-01 | The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects |
| NCT00162305 ↗ | A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects | Completed | AstraZeneca | Phase 2 | 2005-04-01 | The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects |
| NCT00263276 ↗ | A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus | Completed | Bristol-Myers Squibb | Phase 2 | 2005-12-01 | The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied |
| NCT00263276 ↗ | A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus | Completed | AstraZeneca | Phase 2 | 2005-12-01 | The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied |
| NCT00357370 ↗ | A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes | Completed | Bristol-Myers Squibb | Phase 2/Phase 3 | 2006-10-01 | The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone) alone, in subjects with type 2 diabetes. The safety of this treatment will also be studied. |
| NCT00357370 ↗ | A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes | Completed | AstraZeneca | Phase 2/Phase 3 | 2006-10-01 | The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone) alone, in subjects with type 2 diabetes. The safety of this treatment will also be studied. |
| NCT00528372 ↗ | A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise | Completed | Bristol-Myers Squibb | Phase 3 | 2007-09-01 | The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking medication for less than 24 weeks since their original diabetes diagnosis. The safety of this treatment will also be studied. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DAPAGLIFLOZIN
Condition Name
Clinical Trial Locations for DAPAGLIFLOZIN
Trials by Country
Clinical Trial Progress for DAPAGLIFLOZIN
Clinical Trial Phase
Clinical Trial Sponsors for DAPAGLIFLOZIN
Sponsor Name
